Free shipping on all orders over $ 500

KYL peptide

Cat. No. M49948
KYL peptide Structure
Size Price Availability Quantity
1mg USD 170  USD170 In stock
5mg USD 420  USD420 In stock
10mg USD 600  USD600 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

KYL peptide is an antagonistic peptide that selectively targets EphA4, and its binding to the ligand-binding domain of EphA4 effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice. In addition, KYL peptide can promote nerve regeneration after injury and modulate immune response.

Chemical Information
Molecular Weight 1465.73
Formula C74H108N14O17
CAS Number 676657-00-4
Form Solid
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Related Ephrin Receptor Products
EphA2 agonist 1

EphA2 agonist 1 is a potent EphA2 receptor agonist.EphA2 agonist 1 is highly active and selective for EphA2 overexpressing glioma cells and stimulates EphA2 phosphorylation.

LDN-211904 oxalate

LDN-211904 oxalate is a potent and selective EphB3 inhibitor with an IC50 of 0.079 µM.LDN-211904 oxalate showed good metabolic stability in mouse liver microsomes.LDN-211904 oxalate was shown to be effective in inhibiting STAT3-activated CSC stemness in combination with cetuximab.

Ifabotuzumab

Ifabotuzumab is an IgG1κ antibody (KD=610 pM) targeting EphA3. Ifabotuzumab is able to cause apoptosis of tumor cells and activate antibody-dependent cell-mediated cytotoxicity (ADCC), which disrupts the tumor vascular system. In addition, Ifabotuzumab reduces idiopathic pulmonary fibrosis (IPF) CCR10+ cells and ameliorates pulmonary fibrosis.

Eph inhibitor 1

Eph inhibitor 1 is a potent Eph inhibitor.

Urolithin D

Urolithin D is competitive and reversible antagonist of EphA receptors.

  Catalog
Abmole Inhibitor Catalog




Keywords: KYL peptide supplier, Ephrin Receptor, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.